Pembrolizumab in Advanced Hepatocellular Carcinoma as Second-line Treatment After Failure of Sorafenib
Clinical trial NCT03163992 · COMPLETED
Trial details
- NCT number
- NCT03163992
- Sponsor
- Samsung Medical Center
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-12-26
- Primary completion
- 2021-05-17
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.